NCT04837885 - Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 24, 2021

Primary Completion Date

September 24, 2025

Study Completion Date

March 24, 2027

Conditions

Neuroendocrine TumorLiver MetastasesNeuroendocrine Gastroenteropancreatic Tumour

Interventions

PROCEDURE

Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection

Intra-hepatic injection of 68Ga-DOTA-peptides for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)

PROCEDURE

Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection

intravenous injection of 68Ga-DOTA-peptides for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)

DRUG

LUTATHERA® by intra-arterial hepatic (IAH) injection

One treatment dose of LUTATHERA® by IAH injection. The LUTATHERA® by intra-arterial hepatic injection treatment is realised after the conventional treatment by 4 intravenous administrations

PROCEDURE

Scan

Scans after completion of LUTATHERA® treatment injection

Trial Locations (4)

30029

NOT_YET_RECRUITING

Institut de cancérologie du Gard (ICG) - CHU de Nîmes, Nîmes

31100

NOT_YET_RECRUITING

Institut universitaire du cancer de Toulouse (IUCT) Oncopole, Toulouse

33000

NOT_YET_RECRUITING

Institut Bergonié, Bordeaux

33604

RECRUITING

CHU Bordeaux - Hôpital Haut Lévêque, Pessac